



FOR IMMEDIATE RELEASE

Immunotec Opens New Sales Office in Commerce, California, U.S.A.

Vaudreuil, Quebec, Canada – October 21, 2014 Immunotec Inc. is proud to announce the opening of its new Sales Office in Commerce, California, U.S.A. With the considerable growth of Independent Distributors and increased sales throughout the southwestern region of the United States of America, a greater need for support of the regional Independent Distributors has become apparent. As a result, Immunotec has opened a 7,200 square foot full-service sales facility, that is equipped to meet the needs of the Independent Distributors. The office officially opened for business on Monday, October 20, 2014.

“Today marks an important day in Immunotec’s history.” stated company CEO, Mr. Charles L. Orr. “Opening this new sales office in the southwestern region of the United States represents the result of the hard work and dedication of our Distributors who are investing in themselves, their families and everyone they touch as they share our mission to make Immunocal the nutritional choice of households worldwide.”

Festivities to celebrate the opening were held throughout the weekend, including the Grand Opening and Diamond meeting on Thursday, October 16, 2014, a Gold Leadership Seminar on Friday, October 17, 2014 and a University training day on Saturday, October 18, 2014 attended by more than 400 Immunotec Independent Distributors.

About Immunotec Inc.

Immunotec is a Canadian-based Company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S. and Mexico. The Company offers an extensive family of nutritional products targeting health, wellness, weight management, as well as energy and fitness. The Immunocal family of products is supported by over 40 published articles and supporting science in medical and scientific literature.

Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

JP Trottier, Vice-President, Business Development, Immunotec Inc. (450) 510-4452

Patrick Montpetit CPA,CA,CF, Vice-President and Chief Financial Officer, Immunotec Inc. (450) 510-4527.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec’s most recent Management’s Discussion and Analysis, Annual Information Form and Preliminary Short Form Prospectus, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.